In a significant industry move this February, Baxter completed the sale of its kidney care business to The Carlyle Group, creating Vantive—a company now experiencing a unique balance of established expertise and newfound agility.

CEO Chris Toth recently shared Vantive's ambitious vision, highlighting the firm's commitment to investing over $1 billion in digitally-enabled kidney care solutions. Toth discussed how this strategic separation has empowered the company to maintain its valuable legacy while gaining the flexibility to execute decisions more rapidly.

During the conversation, Toth also offered personal insights into his role as a medtech CEO and shared his deep passion for Vantive's mission to transform kidney care.